FSTL5 Protein (His Tag)

01.03.2013

Sino Biological Inc. liefert FSTL5 Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über FSTL5 Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/FSTL5-Protein-g-10537.html

Produkt-Information von FSTL5 Protein

Synonym	FSTL5, KIAA1263
Protein Construction	A DNA sequence encoding the human FSTL5 (Q8N475) (Gln32-Ala847) was expressed with a polyhistidine tag at the C-terminus.
Source	Human
Expression Host	Human Cells

QC Testing von FSTL5 Protein

Purity	> 90% as determined by SDS-PAGE	SDS-PAGE: FSTL5 protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Arg 21
Molecular Mass	The recombinant human FSTL5 consists of 838 amino acids and predicts a molecular mass of 94.9 KDa. It migrates as an approximately 95 KDa band in SDS-PAGE under reducing conditions.
Formulation	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von FSTL5 Protein

Storage	Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Beschreibung von FSTL5 Protein

FSTL5 gene is well expressed, 1.0 times the average gene in this release. The sequence of this gene is defined by 120 GenBank accessions from 113 cDNA clones, some from brain, cerebellum, eye, melanotic melanoma, skin, amygdala, breast and 24 other tissues. FSTL5 gene contains 27 distinct introns. FSTL5 may have molecular function (calcium ion binding) and to localize in various compartments (cytoplasm, extracellular space, extracellular region). FSTL5 expression denoted a dismal prognosis both within and across medulloblastoma subgroups. The addition of FSTL5 immunohistochemistry to existing molecular stratification schemes constitutes a reliable and cost-effective tool for prognostication in future clinical trials of medulloblastoma.

References

Masuda T. et al., 2009, Brain Res. 1249: 61-7.
Kingwell K. 2011, Nat Rev Neurol. 7 (11): 598.
Remke M. et al., 2011, J Clin Oncol. 29 (29): 3852-61.